Peli BioThermal Expands European Manufacturing Centre
News Oct 05, 2017
Peli BioThermal has announced the expansion of its European manufacturing capabilities in France.
This extension is in response to meet the rising requirements of the worldwide transportation of pharmaceuticals throughout Europe and globally.
David Williams, President of Peli BioThermal, said: “I’m pleased to announce the extension of our production capability in France, to manufacture our single use bulk thermal shipper CoolPall™ Vertos. It is an exciting development and customers will benefit from the consistent quality and processes implemented worldwide.
“These significant changes and investments represent the ongoing efforts that Peli BioThermal is making and are a clear indication of our commitment to our customers, the industry and our global expansion of manufacturing and services.”
This implementation of the additional European manufacturing capabilities complements the company’s expanding existing facilities, providing solutions for customers globally, which included the recent introduction of new service centres in Belgium and Puerto Rico.
The latest European expansion demonstrates the company’s commitment to significant investment to serve customers globally and follows the qualification of production of the company’s reusable Crēdo Cube™ line of thermal shippers at its facility in the United Kingdom and the expanded manufacturing capability for the single-use Chronos™ Advance, Chronos™ Express and CoolPall™ Vertos product lines to its facility in the United States.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
Salmonella Cases No Longer Declining in the EUNews
The declining trend of salmonellosis cases in the EU has levelled off according to the annual report on zoonotic diseases. Cases of Salmonella Enteritidis acquired in the EU have increased in humans by 3% since 2014 and in laying hens, the prevalence increased from 0.7% to 1.21% over the same period.